Literature DB >> 1212414

Tissue culture studies of malignant effusions.

R H Whitehead, L E Hughes.   

Abstract

This study reports attempts to culture tumour cells from 51 malignant effusions using standard tissue culture techniques. Cultures proliferating for more than one month were derived from 42 effusions including 24/32 from breast cancer patients and 5/6 from colon carcinomata. The morphology of these cells and their culture characteristics were compared with that of cells derived from a benign effusion. A common cell type--believed to be of mesothelial origin--was found in all cultures. In addition, fibroblastic cells were common and smaller pleomorphic cells, possibly tumour cells, were found in many effusions. The mesothelial cells were often multinucleated and grew for long periods. Although the tumour cells grew in conjunction with the mesothelial cells, all attempts at separation have failed. These studies indicate that cells derived from malignant effusions may be largely of mesothelial origin although tumour cells may also be present. The use of short-term cultures of malignant effusions as the source of cells for use as target cells in cytotoxicity tests and in chemotherapy assays is disscussed.

Entities:  

Mesh:

Year:  1975        PMID: 1212414      PMCID: PMC2024775          DOI: 10.1038/bjc.1975.254

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  7 in total

1.  Cultivation of human breast carcinomas.

Authors:  E Y LASFARGUES; L OZZELLO
Journal:  J Natl Cancer Inst       Date:  1958-12       Impact factor: 13.506

2.  Cultivation of normal and malignant human lung tissue. I. The establishment of three adenocarcinoma cell strains.

Authors:  M V REED; G O GEY
Journal:  Lab Invest       Date:  1962-08       Impact factor: 5.662

3.  Tissue culture studies on pleural effusions from breast carcinoma patients.

Authors:  R Cailleau; B Mackay; R K Young; W J Reeves
Journal:  Cancer Res       Date:  1974-04       Impact factor: 12.701

4.  A human cell line from a pleural effusion derived from a breast carcinoma.

Authors:  H D Soule; J Vazguez; A Long; S Albert; M Brennan
Journal:  J Natl Cancer Inst       Date:  1973-11       Impact factor: 13.506

5.  Primary tissue culture explants of human breast cancer.

Authors:  W F Feller; S E Stewart; J Kantor
Journal:  J Natl Cancer Inst       Date:  1972-04       Impact factor: 13.506

6.  Breast tumor cell lines from pleural effusions.

Authors:  R Cailleau; R Young; M Olivé; W J Reeves
Journal:  J Natl Cancer Inst       Date:  1974-09       Impact factor: 13.506

7.  In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors.

Authors:  D J Giard; S A Aaronson; G J Todaro; P Arnstein; J H Kersey; H Dosik; W P Parks
Journal:  J Natl Cancer Inst       Date:  1973-11       Impact factor: 13.506

  7 in total
  5 in total

1.  Mesothelial cells stimulate the anchorage-independent growth of human ovarian tumour cells.

Authors:  A P Wilson
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

2.  Letter: Implications of the osmolalities of some commonly used tissue culture media.

Authors:  R H Whitehead
Journal:  Br J Cancer       Date:  1976-03       Impact factor: 7.640

3.  Analysis of heteroantisera to cells from human malignant effusions by immunofluorescence and protein A binding.

Authors:  J P Birchall; J J Owen; B S Owen
Journal:  Br J Cancer       Date:  1977-12       Impact factor: 7.640

4.  cis-platinum and ovarian carcinoma. In vitro chemosensitivity of cultured tumour cells from patients receiving high dose cis-platinum as first line treatment.

Authors:  A P Wilson; C H Ford; C E Newman; A Howell
Journal:  Br J Cancer       Date:  1987-12       Impact factor: 7.640

5.  CD90+ mesothelial-like cells in peritoneal fluid promote peritoneal metastasis by forming a tumor permissive microenvironment.

Authors:  Joji Kitayama; Shigenobu Emoto; Hironori Yamaguchi; Hironori Ishigami; Toshiaki Watanabe
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.